Skip to main content

Advertisement

SpringerLink
Log in

Dermatomyositis Diagnosis and Treatment in the Inpatient Setting

  • REVIEW
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Dermatomyositis can present with a range of manifestations and severity that may necessitate hospital admission. Dermatologists are frequently consulted for patients with dermatomyositis inpatient. Herein we describe clinical features and management of multisystem complications of dermatomyositis with a focus on the inpatient setting.

Recent Findings

Patients with dermatomyositis are at risk for hospitalization due to disease flares, infections, and systemic complications. Furthermore, patients may seek care for symptoms including shortness of breath, fever, or cutaneous eruptions which can lead to a new diagnosis of dermatomyositis. Patients with dermatomyositis have increased healthcare utilization and necessitate multidisciplinary and collaborative care. Cutaneous findings may be subtle yet provide important prognostic information. Symptoms arising from skin disease may also be chronic and refractory.

Summary

Dermatologists are essential in both diagnosing and managing dermatomyositis and must be attuned to the multiple systemic manifestations and complications that impact inpatient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County. Minnesota Arch Dermatol. 2010;146(1):26–30.

    Article  PubMed  Google Scholar 

  2. • Ungprasert P, Wannarong T, Cheungpasitporn W, Wijarnpreecha K, Thongprayoon C, Kroner PT. Inpatient burden and resource utilization of polymyositis and dermatomyositis: A 10-year Study of National Inpatient Sample. Joint Bone Spine. 2020;87(4):327–30. Large database study finding that the inpatient prevalence of polymyositis and dermatomyositis over a 10-year period from 2005-2014 is higher than that which would be expected by incidence, and determining that the the associated rates of mortality, morbidity, and resource utilization among this group of inpatients is higher relative to those of other hospitalized patients.

    Article  PubMed  Google Scholar 

  3. Ren Z, Laumann AE, Silverberg JI. Association of dermatomyositis with systemic and opportunistic infections in the United States. Arch Dermatol Res. 2019;311(5):377–87.

    Article  PubMed  Google Scholar 

  4. Gutierrez D, Svigos K, Femia A, Brinster NK, Lo SK. Prominent dyspigmentation in a patient with dermatomyositis and TIF1-gamma autoantibodies. JAAD Case Rep. 2022;22:107–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, et al. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. J Med Econ. 2016;19(7):649–54.

    Article  CAS  PubMed  Google Scholar 

  6. • Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–53. Review discussing the diagnosis of dermatomyositis, with a focus on phenotypes associated with various myositis-specific antibodies, as well as therapies for refractory skin disease.

    Article  PubMed  Google Scholar 

  7. Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2017;21(2):131–6.

    Article  PubMed  Google Scholar 

  8. • Tripathi R, Fernandez AP. Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study. Arch Dermatol Res. 2021;313(6):473–82. Database study finding that hospitalized dermatomyositis patients with malignancy were more likely to be older than 40, female, and socioeconomically different than hospitalized dermatomyositis patients without malignancy. The study also found that the economic cost of hospitalized dermatomyositis patients is increasing.

    Article  PubMed  Google Scholar 

  9. Chandrakasan S, Singh S, Ratho RK, Kumar S, Mishra B. Anasarca as the presenting manifestation of parvovirus B19 associated juvenile dermatomyositis. Rheumatol Int. 2009;29(5):565–7.

    Article  PubMed  Google Scholar 

  10. Shukla M, Patel R, Kuzyshyn H, Feinstein D. Subcutaneous oedema of upper limbs heralding an aggressive form of dermatomyositis. BMJ Case Rep. 2018;2018.

  11. Chai Y, Bertorini TE, Li YD, Mitchell C, Guan H. Limb edema and anasarca associated with severe dermatomyositis: report of four cases. Neuromuscul Disord. 2011;21(6):439–42.

    Article  PubMed  Google Scholar 

  12. Jung KD, Kim PS, Park HY, Kim CR, Byun JY, Lee DY, et al. Dermatomyositis associated with generalized subcutaneous edema and Evans syndrome. J Am Acad Dermatol. 2012;66(1):144–7.

    Article  PubMed  Google Scholar 

  13. Zarrabi K, Choy T, Sweeney K, Desai V, Keresztes R. Paraneoplastic edematous dermatomyositis: A rare syndrome observed in a case of small cell lung cancer. Clin Pract. 2017;7(4):982.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Werner de Castro GR, Appenzeller S, Bertolo MB, Costallat LT. Acute dermatomyositis with subcutaneous generalized edema. Clin Rheumatol. 2006;25(6):898–900.

  15. Concha JSS, Merola JF, Fiorentino D, Werth VP. Re-examining mechanic’s hands as a characteristic skin finding in dermatomyositis. J Am Acad Dermatol. 2018;78(4):769-75.e2.

    Article  PubMed  Google Scholar 

  16. Sohara E, Saraya T, Sato S, Tsujimoto N, Watanabe T, Takata S, et al. Mechanic’s hands revisited: is this sign still useful for diagnosis in patients with lung involvement of collagen vascular diseases? BMC Res Notes. 2014;7:303.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Herath H, Keragala B, Pahalagamage SP, Janappriya G, Kulatunga A, Gunasekera CN. Erythroderma and extensive poikiloderma - a rare initial presentation of dermatomyositis: a case report. J Med Case Rep. 2018;12(1):83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kim SW, Kang YS, Park SH, Lee UH, Park HS, Jang SJ. A case of erythrodermic dermatomyositis associated with gastric cancer. Ann Dermatol. 2009;21(4):435–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ge W, Teng BW, Yu DC, Chen G, Zheng LM, Ding YT. Dermatosis as the initial presentation of gastric cancer: two cases. Chin J Cancer Res. 2014;26(5):632–8.

    PubMed  PubMed Central  Google Scholar 

  20. Miyagawa S, Okazaki A, Minowa R, Shirai T. Dermatomyositis presenting as erythroderma. J Am Acad Dermatol. 1992;26(3 Pt 2):489–90.

    Article  CAS  PubMed  Google Scholar 

  21. Liu ZH, Wang XD. Acute-onset adult dermatomyositis presenting with erythroderma and diplopia. Clin Exp Dermatol. 2007;32(6):751–2.

    Article  CAS  PubMed  Google Scholar 

  22. Nousari HC, Kimyai-Asadi A, Spegman DJ. Paraneoplastic dermatomyositis presenting as erythroderma. J Am Acad Dermatol. 1998;39(4 Pt 1):653–4.

    Article  CAS  PubMed  Google Scholar 

  23. Valdes-Gonzalez G, Chavez-Lopez M, Gallaga-Gutierrez A, Reyes-Garcia A. Dermatomyositis-erythrodermia: clinical presentation not associated to malignancy. A case report Reumatol Clin. 2014;10(1):48–50.

    PubMed  Google Scholar 

  24. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271–82.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Concha JSS, Pena S, Gaffney RG, Patel B, Tarazi M, Kushner CJ, et al. Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. Br J Dermatol. 2020;182(2):410–7.

    Article  CAS  PubMed  Google Scholar 

  26. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol. 2017;44(3):319–25.

    Article  CAS  PubMed  Google Scholar 

  27. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken). 2015;67(5):667–72.

    Article  CAS  PubMed  Google Scholar 

  29. Cao H, Xia Q, Pan M, Zhao X, Li X, Shi R, et al. Gottron papules and Gottron sign with ulceration: a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis. J Rheumatol. 2016;43(9):1735–42.

    Article  CAS  PubMed  Google Scholar 

  30. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776–85.

    Article  CAS  PubMed  Google Scholar 

  31. Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16(12):465.

    Article  PubMed  Google Scholar 

  32. Adams EM, Chow CK, Premkumar A, Plotz PH. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics. 1995;15(3):563–74.

    Article  CAS  PubMed  Google Scholar 

  33. Ahmed S, Concha JSS, Chakka S, Krain RL, Zamalin D, Foulke G, et al. Diagnosing muscle disease in a cohort of classic dermatomyositis patients seen at a rheumatologic dermatology outpatient clinic. J Am Acad Dermatol. 2022;86(3):544–50.

    Article  PubMed  Google Scholar 

  34. Schempp CM, Schauer F, Huhn CK, Venhoff N, Finzel S. Skin inflammation associated with arthritis, synovitis and enthesitis. Part 2: rheumatoid arthritis, reactive arthritis, Reiter's syndrome, Lyme borreliosis, dermatomyositis and lupus erythematosus. J Dtsch Dermatol Ges. 2019;17(2):167–81.

  35. Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Oohata S, Okita H, et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS ONE. 2016;11(5): e0154746.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909–14.

    Article  CAS  PubMed  Google Scholar 

  37. Ebert EC. Review article: the gastrointestinal complications of myositis. Aliment Pharmacol Ther. 2010;31(3):359–65.

    Article  CAS  PubMed  Google Scholar 

  38. Williams RB, Grehan MJ, Hersch M, Andre J, Cook IJ. Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia. Gut. 2003;52(4):471–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82(4):441–7.

    Article  PubMed  Google Scholar 

  40. Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109–29.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Couvrat-Desvergnes G, Masseau A, Benveniste O, Bruel A, Hervier B, Mussini JM, et al. The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore). 2014;93(1):33–41.

    Article  CAS  PubMed  Google Scholar 

  42. Yen TH, Lai PC, Chen CC, Hsueh S, Huang JY. Renal involvement in patients with polymyositis and dermatomyositis. Int J Clin Pract. 2005;59(2):188–93.

    Article  PubMed  Google Scholar 

  43. Akashi Y, Inoh M, Gamo N, Kinashi M, Ohbayashi S, Miyake H, et al. Dermatomyositis associated with membranous nephropathy in a 43-year-old female. Am J Nephrol. 2002;22(4):385–8.

    Article  PubMed  Google Scholar 

  44. Civilibal M, Selcuk Duru N, Ozagari A, Durali K, Elevli M. Immunoglobulin A nephropathy associated with juvenile dermatomyositis. Pediatr Nephrol. 2009;24(10):2073–5.

    Article  PubMed  Google Scholar 

  45. Makino H, Hirata K, Matsuda M, Amano T, Ota Z. Membranous nephropathy developing during the course of dermatomyositis. J Rheumatol. 1994;21(7):1377–8.

    CAS  PubMed  Google Scholar 

  46. Kaneoka H, Sasatomi Y, Miyagi K, Kiyoshi Y, Takeda S, Takebayashi S, et al. A rare case of dermatomyositis associated with immune-complex type glomerulonephritis, idiopathic thrombopenic purpura, pulmonary fibrosis and lung cancer. Clin Exp Rheumatol. 2003;21(6):801–2.

    CAS  PubMed  Google Scholar 

  47. Moriyama T, Uruta Y, Yamaguchi H, Fukuzaki M, Uchida Y, Yasumoto Y, et al. A case of immune-complex type glomerulonephritis associated with dermatomyositis. Nippon Naika Gakkai Zasshi. 1989;78(7):994–5.

    Article  CAS  PubMed  Google Scholar 

  48. Cucchiari D, Angelini C. Renal involvement in idiopathic inflammatory myopathies. Clin Rev Allergy Immunol. 2017;52(1):99–107.

    Article  CAS  PubMed  Google Scholar 

  49. Yuste C, Rapalai M, Pritchard BA, Jones TJ, Amoasii C, Al-Ansari A, et al. Overlap between dermatomyositis and ANCA vasculitides. Clin Kidney J. 2014;7(1):59–61.

    Article  PubMed  Google Scholar 

  50. Xiong A, Hu Z, Zhou S, Qiang Y, Song Z, Chen H, et al. Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies. Rheumatology (Oxford). 2022;61(7):2728–39.

    Article  PubMed  Google Scholar 

  51. Yafasova A, Diederichsen LP, Schou M, Sun G, Torp-Pedersen C, Gislason GH, et al. Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort. J Intern Med. 2021;290(3):704–14.

    Article  CAS  PubMed  Google Scholar 

  52. Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev. 2014;13(10):1048–54.

  53. Danieli MG, Gelardi C, Guerra F, Cardinaletti P, Pedini V, Gabrielli A. Cardiac involvement in polymyositis and dermatomyositis. Autoimmun Rev. 2016;15(5):462–5.

    Article  PubMed  Google Scholar 

  54. Zhang L, Wang GC, Ma L, Zu N. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol. 2012;35(11):686–91.

    CAS  PubMed  Google Scholar 

  55. Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatolog Treat. 2013;24(6):418–21.

    Article  PubMed  Google Scholar 

  56. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol. 2006;54(2):217–20.

    Article  PubMed  Google Scholar 

  57. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011;65(6):1107–16.

    Article  PubMed  PubMed Central  Google Scholar 

  58. • Pinard J, Femia AN, Roman M, Alsarheed A, Joyce C, Lin J, et al. Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers. JAMA Dermatol. 2019;155(4):494–6. Retrospective study examining systemic treatments for clinically amyopathic dermatomyositis at 4 tertiary care centers.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231–3; discussion 3.

  60. Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol. 2017;3(4):189–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):28.

    Article  PubMed  Google Scholar 

  62. Wolstencroft PW, Casciola-Rosen L, Fiorentino DF. Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis. JAMA Dermatol. 2018;154(10):1199–203.

    Article  PubMed  PubMed Central  Google Scholar 

  63. • Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283–96. A review paper discussing initial evaluation in patients suspected of having dermatomyositis, the recommended work-up for malignancy and interstitial lung disease following diagnosis, and treatment options based on disease severity and extent of systemic involvement.

    Article  PubMed  Google Scholar 

  64. Hornung T, Ko A, Tuting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139–42.

    Article  CAS  PubMed  Google Scholar 

  65. Kolla AM, Liu L, Shaw K, Shapiro J, Femia A, Lo SK. A narrative review of therapies for scalp dermatomyositis. Dermatol Ther. 2021;34(6): e15138.

    Article  PubMed  Google Scholar 

  66. Lam C, Vleugels RA. Management of cutaneous dermatomyositis. Dermatol Ther. 2012;25(2):112–34.

    Article  PubMed  Google Scholar 

  67. Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies. Clin Rheumatol. 2017;36(1):239–40.

    Article  PubMed  Google Scholar 

  68. Bounfour T, Bouaziz JD, Bezier M, Cordoliani F, Saussine A, Petit A, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol. 2014;28(9):1150–7.

    Article  CAS  PubMed  Google Scholar 

  69. Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol. 2013;69(4):654–7.

    Article  PubMed  Google Scholar 

  70. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35(2):254–9.

    CAS  PubMed  Google Scholar 

  72. Shimojima Y, Ishii W, Matsuda M, Kishida D, Ikeda SI. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol. 2017;23(2):87–93.

    Article  PubMed  Google Scholar 

  73. Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39(1):192–4.

    PubMed  Google Scholar 

  74. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780–4.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670–7.

    Article  CAS  PubMed  Google Scholar 

  76. Kato M, Ikeda K, Kageyama T, Kasuya T, Kumagai T, Furuya H, et al. Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis. J Clin Rheumatol. 2021;27(8S):S574–7.

    Article  PubMed  Google Scholar 

  77. Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y, et al. JAK-inhibitors for dermatomyositis: a concise literature review. Dermatol Ther. 2021;34(3): e14939.

    Article  CAS  PubMed  Google Scholar 

  78. Werth VP, Hejazi E, Pena SM, Haber J, Zeidi M, Reddy N, et al. Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol. 2022;142(10):2651–9 e1.

  79. Priovant Therapeutics I. A study to investigate the efficacy and safety of brepocitinib in adults with dermatomyositis. https://ClinicalTrials.gov/show/NCT05437263; 2022.

  80. Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017;56(2):247–54.

    Article  CAS  PubMed  Google Scholar 

  81. Argobi Y, Smith GP. Tracking changes in nailfold capillaries during dermatomyositis treatment. J Am Acad Dermatol. 2019;81(1):275–6.

    Article  PubMed  Google Scholar 

  82. Clottu A, Laffitte E, Prins C, Chizzolini C. Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology. 2012;225(4):376–80.

    Article  PubMed  Google Scholar 

  83. Combalia A, Giavedoni P, Tamez L, Grau-Junyent JM, Mascaro JM Jr. Bosentan for Cutaneous Ulcers in Anti-MDA5 Dermatomyositis. JAMA Dermatol. 2018;154(3):371–3.

    Article  PubMed  Google Scholar 

  84. Min HK, Kim HR, Lee SH, Park SH, Oh J, Choi K. Refractory Digital Ulcers Treated by Botulinum Toxin and Endothelin Receptor-1 Antagonist in Anti-MDA5-Antibody-Positive Dermatomyositis. J Clin Neurol. 2020;16(1):160–2.

    Article  PubMed  Google Scholar 

  85. Zhong J, Lan Y, Fu S, Zhang J, Lu S, He Y, et al. Botulinum toxin A injection for treatment of chronic skin ulcer: a case series and literature review. Int J Low Extrem Wounds. 2019;18(1):97–103.

    Article  CAS  PubMed  Google Scholar 

  86. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol. 2011;65(1):15–22; quiz 3–4.

  88. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6(3):129–37.

    Article  PubMed  Google Scholar 

  89. Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28(6):913–21.

    Article  CAS  PubMed  Google Scholar 

  90. Isak V, Jorizzo JL. Recent developments on treatment strategies and the prognosis of dermatomyositis: a review. J Dermatolog Treat. 2018;29(5):450–9.

    Article  PubMed  Google Scholar 

  91. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638–56.

    Article  CAS  PubMed  Google Scholar 

  92. Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011;13(2):119–30.

    Article  PubMed  Google Scholar 

  93. Matsubara S, Sawa Y, Takamori M, Yokoyama H, Kida H. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1994;57(8):1008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Raghu P, Manadan AM, Schmukler J, Mathur T, Block JA. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy. Am J Ther. 2015;22(4):244–7.

    Article  PubMed  Google Scholar 

  95. • Lupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. Int J Womens Dermatol. 2021;7(5Part A):545–51. A review with vase vignettes examining the approach to anticipating and preventing glucocorticoid-induced osteoporosis in patients being treated with glucocorticoids for dermatologic diseases.

  96. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. J Am Acad Dermatol. 2017;76(2):191–8.

    Article  PubMed  Google Scholar 

  97. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol. 2017;76(1):1–9.

    Article  PubMed  Google Scholar 

  98. Zhang Y, Milojevic D. Protecting bone health in pediatric rheumatic diseases: pharmacological considerations. Paediatr Drugs. 2017;19(3):193–211.

    Article  PubMed  Google Scholar 

  99. Cox M, Sandler RD, Matucci-Cerinic M, Hughes M. Bone health in idiopathic inflammatory myopathies. Autoimmun Rev. 2021;20(4): 102782.

    Article  CAS  PubMed  Google Scholar 

  100. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. J Am Acad Dermatol. 2017;76(2):201–7.

    Article  PubMed  Google Scholar 

  101. Hsu HC, Chang YS, Hou TY, Chen LF, Hu LF, Lin TM, et al. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol. 2021;40(9):3755–63.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Jagannathan M. The infectious danger of corticosteroids: a fatal case of Pneumocystis jirovecii pneumonia in a non-HIV patient following corticosteroid use with prophylaxis. Cureus. 2019;11(10): e5874.

    PubMed  PubMed Central  Google Scholar 

  103. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128.

    Article  CAS  PubMed  Google Scholar 

  104. Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8.

    Article  PubMed  Google Scholar 

  105. Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1(2):99–102.

    Article  CAS  PubMed  Google Scholar 

  106. Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol. 2015;11(11):1265–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018;97(2): e9639.

    Article  PubMed  Google Scholar 

  108. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.

  109. Corrado B, Ciardi G, Lucignano L. Supervised physical therapy and polymyositis/dermatomyositis-a systematic review of the literature. Neurol Int. 2020;12(3):77–88.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Emily Z. Hejazi and Lavanya Mittal shared first authors, Alisa N. Femia and Avrom S. Caplan shared last authors.

Authors and Affiliations

  1. The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, 222 East 41st Street, 16th Floor, New York, NY, 10016, USA

    Emily Z. Hejazi, Lavanya Mittal, Kristen Lo Sicco, Daniel R. Mazori, Alisa N. Femia & Avrom S. Caplan

Authors
  1. Emily Z. Hejazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lavanya Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristen Lo Sicco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel R. Mazori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alisa N. Femia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Avrom S. Caplan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avrom S. Caplan.

Ethics declarations

Conflict of Interest

Drs. Hejazi, Mittal, Mazori and Caplan have no conflicts of interest. Dr. Lo Sicco reports consulting fees from Pfizer and Aquis outside the submitted work. Dr. Femia reports consulting fees from Timber Pharmaceuticals and Octagon Therapeutics outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hejazi, E.Z., Mittal, L., Sicco, K.L. et al. Dermatomyositis Diagnosis and Treatment in the Inpatient Setting. Curr Derm Rep 12, 56–68 (2023). https://doi.org/10.1007/s13671-023-00389-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-023-00389-6

Keywords

Search

Navigation